CoChat

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

Open access

The DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index.

Abstract

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin were examined. Twenty-four Wistar albino rats were distributed in four different groups, and a high-fat diet and streptozotocin were used to induce type 2 in two groups. Rats in the untreated control groups were administered 0.9% NaCl solution over a 6-week period, and those in the treatment groups were administered 0.9% NaCl for 3 weeks, followed by subcutaneous injection of liraglutide (150 μg/kg) for an additional 3 weeks. In the liraglutide-treated diabetic group, the heart-to-body weight ratio was significantly reduced, levels of cardiac biomarkers, troponin I and creatine-kinase-MB, were improved; activities of antioxidant enzymes, glutathione peroxidase and superoxide dismutase, were increased; and levels of malondialdehyde were decreased. Western blotting and immunohistochemical studies revealed increased levels of ILK, P-PI3K, P-AKT, and BCL2, as well as those of caspase 3, BAX, and P-PTEN, indicating mitigation of cardiomyocyte apoptosis. Our results show that liraglutide, by targeting GLP1Rs, enhances the expression of proteins in the ILK/PI3K/AKT/PTEN pathway and thereby exerts its cardioprotective effects in rats with DCM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph17030374

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Liraglutide treatment effect on serum cardiac biomarkers in rats with diabetes. (A) Troponin I levels. (B) Creatine kinase-MB (CK-MB) levels. Data are presented as means ± standard error of the mean (SEM) (n = 6 samples per group). One-way analysis of variance (ANOVA) was performed for comparison of data, followed by the Tukey–Kramer post hoc test. CN, normal control group; CD, diabetic control group; LN, nondiabetic group treated with liraglutide; LD, diabetic group treated with liraglutide. Significant differences are denoted as *** p < 0.001 in comparison to the CN group; * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to the CD group.
Figure 1 Liraglutide treatment effect on serum cardiac biomarkers in rats with diabetes. (A) Troponin I levels. (B) Creatine kinase-MB (CK-MB) levels. Data are presented as means ± standard error of the mean (SEM) (n = 6 samples per group). One-way analysis of variance (ANOVA) was performed for comparison of data, followed by the Tukey–Kramer post hoc test. CN, normal control group; CD, diabetic control group; LN, nondiabetic group treated with liraglutide; LD, diabetic group treated with liraglutide. Significant differences are denoted as *** p < 0.001 in comparison to the CN group; * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to the CD group.CC BY · PubMed Central
Figure 2 Liraglutide alleviated the effect of streptozotocin on the cardiac structure of the heart tissue of rats. The hematoxylin and eosin-stained heart tissue sections from (A) rats in the normal control group and (B) in normal rats that were administered liraglutide showing typical histological features of myocardial cell cytoplasm and nuclei. (C) Myocardial cells in sections from diabetic rats showing cytoplasm degeneration and pyknotic nuclei. (D) Sections from diabetic rats that were administered liraglutide showing lesser degeneration of cytoplasm and nuclei in the myocardial cells. Scale bar = 50 μm (original magnification, ×50).
Figure 2 Liraglutide alleviated the effect of streptozotocin on the cardiac structure of the heart tissue of rats. The hematoxylin and eosin-stained heart tissue sections from (A) rats in the normal control group and (B) in normal rats that were administered liraglutide showing typical histological features of myocardial cell cytoplasm and nuclei. (C) Myocardial cells in sections from diabetic rats showing cytoplasm degeneration and pyknotic nuclei. (D) Sections from diabetic rats that were administered liraglutide showing lesser degeneration of cytoplasm and nuclei in the myocardial cells. Scale bar = 50 μm (original magnification, ×50).CC BY · PubMed Central
Figure 3 Liraglutide treatment effects on cardiac oxidative stress markers in rats with diabetes. (A) Malondialdehyde (MDA) levels. (B) Superoxide dismutase (SOD) activity. (C) Glutathione peroxidase (GPx) activity. Data are exhibited in the form of means ± SEM (n = 6 samples in each group). One-way ANOVA was used for inter-group comparisons, then the Tukey–Kramer post hoc test. CN, normal control group; CD diabetic control group; LN, nondiabetic rats receiving liraglutide treatment; LD, diabetic rats receiving liraglutide treatment. Differences reaching a level of significance are indicated as ** p < 0.01 and *** p < 0.001 compared with the normal control group (CN), and * p < 0.05; ** p < 0.01 compared with the control group containing diabetic rats (CD).
Figure 3 Liraglutide treatment effects on cardiac oxidative stress markers in rats with diabetes. (A) Malondialdehyde (MDA) levels. (B) Superoxide dismutase (SOD) activity. (C) Glutathione peroxidase (GPx) activity. Data are exhibited in the form of means ± SEM (n = 6 samples in each group). One-way ANOVA was used for inter-group comparisons, then the Tukey–Kramer post hoc test. CN, normal control group; CD diabetic control group; LN, nondiabetic rats receiving liraglutide treatment; LD, diabetic rats receiving liraglutide treatment. Differences reaching a level of significance are indicated as ** p < 0.01 and *** p < 0.001 compared with the normal control group (CN), and * p < 0.05; ** p < 0.01 compared with the control group containing diabetic rats (CD).CC BY · PubMed Central
Figure 4 Liraglutide treatment’s effects on caspase 3, BAX, and Bcl2 expression in the heart tissue of rats with diabetes. Photomicrographs showing caspase 3 (A) and BAX (B) immunostaining of the heart sections: (CN) shows normal myocardium cytoplasm and nuclei, (CD) shows strong immunoreactivity in myocardium cell nuclei and moderate immunoreactivity in the cytoplasm (black arrow), (LN) exhibits lack of immunopositive cytoplasm and nuclei, and (LD) shows reduced and few immunopositive nuclei. Bcl2 (C): (CN) shows normal myocardium cytoplasm, (CD) shows strong immunoreactivity in myocardium cell nuclei and moderate immunoreactivity in the cytoplasm, (LN) exhibiting the absence of immunopositive cytoplasm, and (LD) shows a significant reduction in the expression and few immunopositive nuclei. Scale bar = 50 μm; magnification, ×20. Semi-quantification results for caspase 3 (D), BAX (E), and Bcl2 (F) immunoreactivity (using ImageJ software, version 1.8.0_172). Data are expressed as mean ± SEM (n = 3 different analyses per group). Statistical analyses were performed using one-way ANOVA; ** p < 0.01, *** p < 0.001 compared to CD. Abbreviations: CN: normal control rats; CD: diabetic control rats; LN: liraglutide-treated normal rats; LD: liraglutide-treated diabetic rats.
Figure 4 Liraglutide treatment’s effects on caspase 3, BAX, and Bcl2 expression in the heart tissue of rats with diabetes. Photomicrographs showing caspase 3 (A) and BAX (B) immunostaining of the heart sections: (CN) shows normal myocardium cytoplasm and nuclei, (CD) shows strong immunoreactivity in myocardium cell nuclei and moderate immunoreactivity in the cytoplasm (black arrow), (LN) exhibits lack of immunopositive cytoplasm and nuclei, and (LD) shows reduced and few immunopositive nuclei. Bcl2 (C): (CN) shows normal myocardium cytoplasm, (CD) shows strong immunoreactivity in myocardium cell nuclei and moderate immunoreactivity in the cytoplasm, (LN) exhibiting the absence of immunopositive cytoplasm, and (LD) shows a significant reduction in the expression and few immunopositive nuclei. Scale bar = 50 μm; magnification, ×20. Semi-quantification results for caspase 3 (D), BAX (E), and Bcl2 (F) immunoreactivity (using ImageJ software, version 1.8.0_172). Data are expressed as mean ± SEM (n = 3 different analyses per group). Statistical analyses were performed using one-way ANOVA; ** p < 0.01, *** p < 0.001 compared to CD. Abbreviations: CN: normal control rats; CD: diabetic control rats; LN: liraglutide-treated normal rats; LD: liraglutide-treated diabetic rats.CC BY · PubMed Central
Figure 5 Liraglutide treatment’s effect on myocardial apoptosis in rats with type 2 diabetes induced via STZ/high-fat diet (HFD). (A) Photomicrographs showing TUNEL staining of the heart tissue sections from normal control rats (CN), diabetic control rats (CD), liraglutide-treated normal rats (LN), and liraglutide-treated diabetic rats (LD). TUNEL-positive cells are indicated by orange arrows and are displayed in light blue (original magnification, ×100). (B) Quantification of TUNEL-positive cells in the heart tissue sections from diabetic rats, expressed as a percentage of total nuclei detected using DAPI staining. Data are presented as means ± SEM (n = 4 randomly selected fields per slide, with each slide representing one tissue sample, totaling six samples per group). *** p < 0.001 in comparison to normal and diabetic controls, respectively.
Figure 5 Liraglutide treatment’s effect on myocardial apoptosis in rats with type 2 diabetes induced via STZ/high-fat diet (HFD). (A) Photomicrographs showing TUNEL staining of the heart tissue sections from normal control rats (CN), diabetic control rats (CD), liraglutide-treated normal rats (LN), and liraglutide-treated diabetic rats (LD). TUNEL-positive cells are indicated by orange arrows and are displayed in light blue (original magnification, ×100). (B) Quantification of TUNEL-positive cells in the heart tissue sections from diabetic rats, expressed as a percentage of total nuclei detected using DAPI staining. Data are presented as means ± SEM (n = 4 randomly selected fields per slide, with each slide representing one tissue sample, totaling six samples per group). *** p < 0.001 in comparison to normal and diabetic controls, respectively.CC BY · PubMed Central
Figure 6 Effect of liraglutide on the levels of integrin-linked kinase (ILK), P-PI3K, P-AKT, and P-PTEN. (A) Representative images of Western blots for P-PI3K, P-AKT, ILK, and P-PTEN using the heart tissue lysates. Normal control rats (CN); diabetic controlrats (CD); liraglutide-treated normal rats (LN); and liraglutide-treated diabetic rats (LD). (B–E) Quantification of bands for P-PI3K (B), P-AKT (C), ILK (D), and P-PTEN (E) using ImageJ software. Normalization was performed using total PI3K and AKT for P-PI3K and P-AKT levels, respectively, whereas β-actin levels were used for normalization of ILK and P-PTEN levels. Levels of expression are presented in the form of fold induction relative to normal rats in the control group. Data are exhibited in the form of means ± SEM (n = 4 samples from four rats in each group). One-way ANOVA and then the Tukey–Kramer post hoc test was used for statistical analyses and inter-group comparisons. Levels of significance are expressed as ** p < 0.01, *** p < 0.001 compared with the control group containing normal rats, and * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group containing diabetic rats.
Figure 6 Effect of liraglutide on the levels of integrin-linked kinase (ILK), P-PI3K, P-AKT, and P-PTEN. (A) Representative images of Western blots for P-PI3K, P-AKT, ILK, and P-PTEN using the heart tissue lysates. Normal control rats (CN); diabetic controlrats (CD); liraglutide-treated normal rats (LN); and liraglutide-treated diabetic rats (LD). (B–E) Quantification of bands for P-PI3K (B), P-AKT (C), ILK (D), and P-PTEN (E) using ImageJ software. Normalization was performed using total PI3K and AKT for P-PI3K and P-AKT levels, respectively, whereas β-actin levels were used for normalization of ILK and P-PTEN levels. Levels of expression are presented in the form of fold induction relative to normal rats in the control group. Data are exhibited in the form of means ± SEM (n = 4 samples from four rats in each group). One-way ANOVA and then the Tukey–Kramer post hoc test was used for statistical analyses and inter-group comparisons. Levels of significance are expressed as ** p < 0.01, *** p < 0.001 compared with the control group containing normal rats, and * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group containing diabetic rats.CC BY · PubMed Central
Figure 7 Schematic of the study design.
Figure 7 Schematic of the study design.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 15

Metadata

Authors
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M.
Affiliations
  • King Saud University (SA)
  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
  • Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2024-03-15
Volume
17
Issue
3
Pages
374
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4392858803
Cited by
13
References
80
Citations by year
2026: 2 · 2025: 8 · 2024: 3
FWCI
4.28
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Ministry of Education in Saudi Arabia (IFKSUDR_H150)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
liraglutide, diabetic cardiomyopathy, type 2 diabetes, integrin-linked kinase, PI3K/Akt signaling, PTEN, GLP-1 receptor agonists, streptozotocin-induced diabetes, cardiomyocyte apoptosis, oxidative stress, cardioprotection, Bcl-2, caspase-3, Bax

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.3390/ph17030374
The paper
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M. (2024). Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals. https://doi.org/10.3390/ph17030374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.